J&J mulls $20B deal for device maker Synthes

When a Morgan Stanley analyst recently concluded that Johnson & Johnson could do a deal bigger than $10 billion, he wasn't kidding. J&J is in talks to buy Synthes, which makes devices for bone fractures and trauma, for some $20 billion. It would be the biggest deal in J&J history, but that might be just the right size at this point, at least financially; the company has $19 billion in cash on hand.

Rumors had been swirling that J&J might buy device maker Smith & Nephew, which makes hip and knee replacements. But analysts see Synthes as a better addition to the company's wide range of businesses. "If I were J&J, I would rather buy Synthes," Sanford C. Bernstein's Lisa Bedell Clive told Bloomberg. "It's the chance to become the market leader in trauma." And trauma is one of the fastest-growing segments of the orthopedic device market, the Wall Street Journal notes, with 8 percent growth last year. "It's the gaping hole in [J&J's] orthopedic portfolio," a source told the WSJ, "so Synthes really is a good match for them."

Despite analyst cheer about the news, the deal would require regulatory approval, which could be difficult to get. And it may also require approval by a surgical research group, AO Foundation, which is affiliated with Synthes. Furthermore, integrating Synthes into the J&J fold could distract from the company's focus on its manufacturing problems. The company has recalled millions of packages of over-the-counter and prescription drugs; it's cooperating with at least two government probes; and it's fighting hundreds of patient lawsuits, including 600 involving faulty hip replacement devices.

"You could make a fair argument it's not the right time to expand," T. Rowe Price analyst Mark Bussard told Bloomberg. "If I were on their board, I might be asking, ‘Why don't we spend the next year getting our house in order, and then talk about a $20 billion acquisition?'"

- see the WSJ coverage
- get more from Bloomberg
- check out the Reuters story

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.